Aura Biosciences, Inc. Payments to Acquire Marketable Securities
Aura Biosciences, Inc. (AURA) reported Payments to Acquire Marketable Securities of $256.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- Aura Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00.
- Aura Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $73.97M, a 269.91% increase year-over-year.
- Aura Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-06-30 was $9.98M, a 0.81% increase year-over-year.
- Aura Biosciences, Inc. payments to acquire marketable securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Aura Biosciences, Inc. payments to acquire marketable securities for fiscal 2025 was $83.96M, a 42.05% increase from fiscal 2024.
- Aura Biosciences, Inc. payments to acquire marketable securities for fiscal 2024 was $59.10M, a 74.70% decline from fiscal 2023.
- Aura Biosciences, Inc. payments to acquire marketable securities for fiscal 2023 was $233.65M, a 95.06% increase from fiscal 2022.
- Aura Biosciences, Inc. payments to acquire marketable securities for fiscal 2022 was $119.78M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $256.01M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $73.97M derived: sum of 2 quarters · filed 2026-03-30 | $83.96M derived: sum of 3 quarters · filed 2026-08-11 | $83.96M 10-K · filed 2026-03-30 |
| 2025-09-30 | $73.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $83.96M derived: sum of 2 quarters · filed 2026-08-11 | $83.96M 10-Q · filed 2025-11-13 | $83.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $9.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $9.98M 10-Q · filed 2026-08-11 | $9.98M derived: sum of 3 quarters · filed 2026-08-11 | $29.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $20.00M derived: sum of 3 quarters · filed 2026-03-30 | $29.90M derived: sum of 4 quarters · filed 2026-03-30 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $20.00M derived: sum of 2 quarters · filed 2026-03-30 | $29.90M derived: sum of 3 quarters · filed 2026-03-30 | $59.10M 10-K · filed 2026-03-30 |
| 2024-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $29.90M derived: sum of 2 quarters · filed 2025-11-13 | $59.10M 10-Q · filed 2025-11-13 | $203.91M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $39.10M 10-Q · filed 2025-08-13 | $183.91M derived: sum of 3 quarters · filed 2025-08-13 | $183.91M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $29.20M 10-Q · filed 2025-05-15 | $174.00M derived: sum of 2 quarters · filed 2025-05-15 | $174.00M derived: sum of 3 quarters · filed 2025-05-15 | $174.00M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $144.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $144.80M derived: sum of 2 quarters · filed 2025-03-24 | $144.80M derived: sum of 3 quarters · filed 2025-03-24 | $233.65M 10-K · filed 2025-03-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $88.85M 10-Q · filed 2024-11-12 | $137.37M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $88.85M 10-Q · filed 2024-08-08 | $137.37M derived: sum of 3 quarters · filed 2024-08-08 | $137.37M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $88.85M 10-Q · filed 2024-05-09 | $137.37M derived: sum of 2 quarters · filed 2024-05-09 | $137.37M derived: sum of 3 quarters · filed 2024-05-09 | $183.73M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $48.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $48.52M derived: sum of 2 quarters · filed 2024-03-27 | $94.89M derived: sum of 3 quarters · filed 2024-03-27 | $119.78M 10-K · filed 2024-03-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $46.37M derived: sum of 2 quarters · filed 2023-11-09 | $71.27M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $46.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $71.27M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $24.90M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |